Beta-blocker bashing and downgrading in hypertension management: a fashionable trend representing a matter of concern-Reference-Cited by-同舟云学术

Beta-blocker bashing and downgrading in hypertension management: a fashionable trend representing a matter of concern

Published:2024-05-01 Issue:6 Volume:42 Page:966-967
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:

Author:

Kreutz Reinhold¹,Brunström Mattias²,Burnier Michel³,Grassi Guido⁴,Januszewicz Andrzej⁵,Kjeldsen Sverre E.⁶⁷,Muiesan Maria L.⁸,Thomopoulos Costas⁹,Tsioufis Konstantinos¹⁰,Mancia Giuseppe¹¹

Affiliation:

1. Charite-Universitätsmedizin Berlin, Institute of Clinical Pharmacology and Toxicology, Germany

2. Department of Public Health and Clinical Medicine, Umea University, Sweden

3. Faculty of Biology and Medicine, University of Lausanne, Switzerland

4. Clinica Medica, University Milano-Bicocca, Milan, Italy

5. Department of Hypertension, National Institute of Cardiology, Warsaw, Poland

6. Institute for Clinical Medicine, University of Oslo

7. Departments of Cardiology and Nephrology, Ullevaal Hospital, Oslo, Norway

8. OC 2 Medicina, ASST Spedali Civili di Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Italy

9. Department of Cardiology, General Hospital of Athens “Laiko”

10. First Department of Cardiology, Medical School, University of Athens, Hippokration Hospital, Athens, Greece

11. University Milano-Bicocca, Italy

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference7 articles.

1. The 2023 European Society of Hypertension guidelines: cause for concern;Shantsila;J Hypertens,2024

2. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA);Mancia;J Hypertens,2023

3. β blockers switched to first-line therapy in hypertension;Messerli;Lancet,2023

4. Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified;Esler;Blood Press,2022

5. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines;Mancia;Hypertension,2022